

**HSD17B6 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP9516a****Specification**

---

**HSD17B6 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [O14756](#)**HSD17B6 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 8630**Other Names**

17-beta-hydroxysteroid dehydrogenase type 6, 17-beta-HSD 6, 17-beta-HSD6, 3-alpha->beta-hydroxysteroid epimerase, 3-alpha->beta-HSE, Oxidative 3-alpha hydroxysteroid dehydrogenase, HSD17B6, RODH

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**HSD17B6 Antibody (N-term) Blocking Peptide - Protein Information****Name** HSD17B6**Synonyms** RODH, SDR9C6**Function**

NAD-dependent oxidoreductase with broad substrate specificity that shows both oxidative and reductive activity (in vitro). Has 17- beta-hydroxysteroid dehydrogenase activity towards various steroids (in vitro). Converts 5-alpha-androstan-3-alpha,17-beta-diol to androsterone and estradiol to estrone (in vitro). Has 3-alpha-hydroxysteroid dehydrogenase activity towards androsterone (in vitro). Has retinol dehydrogenase activity towards all-trans-retinol (in vitro). Can convert androsterone to epi-androsterone. Androsterone is first oxidized to 5-alpha-androstane-3,17-dione and then reduced to epi- andosterone. Can act on both C-19 and C-21 3-alpha-hydroxysteroids.

**Cellular Location**

Microsome membrane; Peripheral membrane protein; Luminal side. Early endosome membrane; Peripheral membrane protein; Luminal side

**Tissue Location**

Detected in liver and prostate (at protein level). Detected in adult liver, lung, brain, placenta,

prostate, adrenal gland, testis, mammary gland, spleen, spinal cord and uterus. Detected in caudate nucleus, and at lower levels in amygdala, corpus callosum, hippocampus, substantia nigra and thalamus. Detected in fetal lung, liver and brain.

### **HSD17B6 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **HSD17B6 Antibody (N-term) Blocking Peptide - Images**

### **HSD17B6 Antibody (N-term) Blocking Peptide - Background**

HSD17B6 has both oxidoreductase and epimerase activities and is involved in androgen catabolism. The oxidoreductase activity can convert 3 alpha-adiol to dihydrotestosterone, while the epimerase activity can convert androsterone to epi-androsterone. Both reactions use NAD<sup>+</sup> as the preferred cofactor.

### **HSD17B6 Antibody (N-term) Blocking Peptide - References**

Ewens, K.G., et al. J. Clin. Endocrinol. Metab. (2010) In press : Jones, M.R., et al. J. Clin. Endocrinol. Metab. 94(12):5034-5038(2009) Persson, B., et al. Chem. Biol. Interact. 178 (1-3), 94-98 (2009) : Belyaeva, O.V., et al. Endocrinology 148(5):2148-2156(2007) Jones, M.R., et al. Fertil. Steril. 86(5):1438-1446(2006) Chetyrkin, S.V., et al. Arch. Biochem. Biophys. 386(1):1-10(2001) Kedishvili, N.Y., et al. Chem. Biol. Interact. 130-132 (1-3), 457-467 (2001) :